Figure 1: Duration Of Survival In Study 1 (Mvasi 01)
Mvasi Injection, Solution
Product Images NDC 55513-206
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Mvasi (NDC 55513-206). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Duration Of Survival In Study 4 (Mvasi 02)
This is a graph showing the proportion surviving over a period of 48 months after a randomized treatment. The graph includes two treatment groups: one with chemotherapy only and the other with chemotherapy plus Bevacizumab. The text also shows the number of participants at risk in each treatment group at different time points.*
Figure 3: Duration Of Survival In Study 5 (Mvasi 03)
This appears to be a chart or graph related to a medical study. It includes categories like "Proportion Surviving," "No. of Patients at Risk," and "Duration of Survival (months)." There are also abbreviations for "PC" and "Bev" and a number of numerical values. However, without more context it is difficult to determine the exact meaning or significance of this data.*
Figure 4: Progression Free Survival In Study 8 (Mvasi 04)
Figure 5: Study 9: Overall Survival For Chemotherapy Vs. Chemotherapy Plus Bevacizumab (Mvasi 05)
Mvasi 06
This text is a table showing the number of patients at risk and the progression-free survival in months, with different values for CPP, CPBI5, and CPBI5H. The number of patients for each value is also provided. There is no available information on what this table is representing or what CPP, CPBI5, and CPBI5H stand for.*
Principal Display Panelpdp Text And Pdp Image For 100 mg:100 mg/4 mLmvasi™(bevacizumab-awwb)injectionndc 55513-206-01single Dose Vialdiscard Unused Portion100 mg/4 mL (25 mg/ml)contains 1 Single Dose Vialfor Intravenous Infusion After Dilutionstore Refrigerated At 2°c To 8°c (36°f To 46°f).protect From Light. Do Not Freeze Or Shakesterile Solution – No Preservativethis Product Contains Dry Natural Rubber.rx Onlyamgen® (Mvasi 07)
This appears to be a chart or graph displaying the "Duration of Progression-free Survival" in months for two different treatments, "CT" (with 182 subjects) and "CT+Bev" (with 179 subjects). The percentages appear to represent the "Proportion Progression-free" at certain time points. Without further context, it is difficult to provide more information or specific insights.*
Principal Display Panelpdp Text And Pdp Image For 400 mg:400 mg/16 mLmvasi™(bevacizumab-awwb)injectionndc 55513-207-01single Dose Vialdiscard Unused Portion400 mg/16 mL (25 mg/ml)contains 1 Single Dose Vialfor Intravenous Infusion After Dilutionstore Refrigerated At 2°c To 8°c (36°f To 46°f). Protect From Light. Do Not Freeze Or Shakesterile Solution – No Preservativethis Product Contains Dry Natural Rubber.rx Onlyamgen® (Mvasi 08)
Mvasi 09
The text provided seems to be a combination of numerical values and labels without a clear context or objective. With this information only, it is not possible to generate a useful description.*
Mvasi 10
This is a description of a medication labeled as NDC55513-206-01. It is a sterile solution intended for intravenous infusion after dilution. The concentration is 100 mg/4 mL (25 mg/mL). It is packaged as a single-dose vial and any unused portion should be discarded. The medication must be stored refrigerated at a temperature range of 2°C to 8°C (36°F to 46°F) to protect it from light. The solution must not be frozen or shaken. This medication does not contain any preservatives. The text also indicates that this medication is available by prescription only.*
Mvasi 11
This is a description of a drug called MVASI, which contains bevacizumab-awnt. It is available in two strengths, 400mg/16 mL and 300mg/16 mL, and is administered through intravenous infusion after dilution. The drug must be stored in a cool, dark place and should not be frozen or shaken. This is a sterile solution that should only be used with a prescription.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
